Feasibility of buprenorphine maintenance therapy programs in the ukraine: First promising treatment outcomes

European Addiction Research

Volumn 15, Issue 3, 2009, Pages 157-162

  Schaub, Michael ^a   Subata, Emilis ^b   Chtenguelov, Victor ^c   Weiler, Gundo ^d   Uchtenhagen, Ambros ^a  

^a Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

^b Medical Faculty   (Lithuania)

^c UKRAINIAN INSTITUTE ON PUBLIC HEALTH POLICY   (Ukraine)

^d WHO Country Office in Ukraine   (Ukraine)

Author keywords

Buprenorphine; Human immunodeficiency virus; Injection drug use; Opiate substitution therapy; Ukraine

Indexed keywords

BUPRENORPHINE;

ADULT; ARTICLE; DISEASE TRANSMISSION; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EMPLOYMENT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SOCIAL STATUS; SUBSTANCE ABUSE; TREATMENT OUTCOME; UKRAINE; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME; UKRAINE;

EID: 65449137963     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000217586     Document Type: Article

References (9)

1. Lawrinson P, Ali R, Buavirat A, Chiamwong- paet S, Dvoryak S, Habrat B, Jie S, Mardiati R, Mokri A, Moskalewicz J, Newcombe D, Poznyak V, Subata E, Uchtenhagen A, Utami DS, Vial R, Zhao C: Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/ AIDS. Addiction 2008;103:1484-1492.
2. UNAIDS: AIDS Epidemic Update: December 2007. Geneva, WHO/UNAIDS.
3. WHO, UNAIDS, UNODC: Joint WHO/ UNDAIDS/UNODC Mission on Opioid Substitution Therapy in Ukraine. 2005.
4. Bruce RD, Dvoryak S, Sylla L, Altice FL: HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenor- phine for IDUs in Ukraine: programme description and policy implications. Int J Drug Policy 2007;18:326-328.
5. Booth RE, Kennedy J, Brewster T, Semerik O: Drug injectors and dealers in Odessa, Ukraine. J Psychoactive Drugs 2003; 35: 419-426.
6. Booth RE, Kwiatkowski CF, Mikulich-Gilb- ertson SK, Brewster JT, Salomonsen-Sautel S, Corsi KF, Sinitsyna L: Predictors of risky needle use following interventions with injection drug users in Ukraine. Drug Alcohol Depend 2006;82:S49-S55.
7. Sullivan LE, Bruce RD, Haltiwanger D, Lucas GM, Eldred L, Finkelstein R, Fiellin DA: Initial strategies for integrating buprenor- phine into HIV care settings in the United States. Clin Infect Dis 2006; 43:191-196.
8. McLellan AT, Kushner H, Metzger D, Peters F: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9:199-213.
9. Fry CL, Lintzeris N: Psychometric properties of the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV- TRAQ). Addiction 2003;98:171-178.